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Zastrow L, Ferrero L, Herrling T, Groth N (2004) Integrated sun protection factor: a new sun protection factor based on free radicals generated by UV irradiation. TO THE EDITOR The relative contribution of erythroid, dermal, and hepatic ferrochelatase (FECH) genotype and enzyme deficiency to dermal photosensitivity and liver disease in erythropoietic protoporphyria (EPP) is not entirely elucidated. A better understanding is critical when treatment options are discussed. A previous publication in the Journal of Investigative Dermatology (Pawliuk et al., 2005) highlighted these issues and elicited subsequent contributions to the discussion (Elder, 2005; Leboulche and Mathews-Roth, 2005; Lim, 2005) . Pawliuk et al. (2005) transplanted bone marrow from an EPP mouse model to normal recipients. Despite elevated protoporphyrin levels, the recipients did not develop cutaneous photosensitivity or liver disease. In a second experiment, photosensitivity did not develop in skin transplanted from normal mice to EPP mice. The authors suggested that elevated protoporphyrin levels alone are insufficient to generate photosensitivity or liver disease in EPP, and that restoration of dermal FECH activity should potentially minimize photosensitivity.
The conclusions drawn from the mouse model do not seem to apply to human EPP. The accumulated experience from different clinical situations, including organ transplantation in humans, points to differences between EPP in mice and humans, and may enable some preliminary conclusions to be drawn.
In mice, an elevated protoporphyrin level after transplanting EPP marrow into healthy mice is insufficient to generate photosensitivity (Pawliuk et al., 2005) and does not cause liver disease (Fontanellas et al., 2000) . A corresponding human situation would be adult onset EPP caused by acquired somatic FECH mutations associated with myelodysplastic syndrome. Several reports (Sassa et al., 2002) have described cases with elevated protoporphyrin levels, severe photosensitivity, and even protoporphyric liver disease (Goodwin et al., 2006) despite normal genotype and FECH activity outside the marrow.
The experiment with transplantation of normal skin to EPP mice suggested that restoration of dermal FECH activity could prevent photosensitivity. This cannot be refuted by referring to experience in human EPP. Two other examples might be considered corresponding human situations, in which dermal cells with normal FECH geno-type have to handle excess protoporphyrin. In photodynamic therapy, proto porphyrin is accumulated after topical administration of aminolevulinic acid despite normal FECH activity (Krammer and Plaetzer, 2008) . The subsequent local photosensitivity forms the basis for photodynamic therapy. In the recently described new form of porphyria, x-linked dominant protoporphyria (Whatley et al., 2008) , protoporphyrin accumulates as ferrochelatase cannot keep up with an increased protoporphyrin load despite normal FECH activity. Whether cellular protoporphyrin levels in these different situations are comparable has never been studied. It still seems unlikely that mere restoration of dermal FECH activity would suffice to prevent photosensitivity in EPP if the protoporphyrin load remains high.
The fact that hematopoietic stem cell transplantation (HSCT) does not entirely normalize circulating protoporphyrin levels or reverse liver damage in mice (Fontanellas et al., 2000) , indicate that the mouse model has a larger proportion of circulating protoporphyrin of non-erythroid origin, although strains may be heterogeneous (Abitbol et al., 2005) . Among the few human cases that have been treated by HSCT, porphyrin levels were completely normalized, which cured photosensitivity and prevented recurrence of liver disease (Rand et al., 2006) , even when HSCT was done without a preceding liver transplantation (Wahlin et al., 2007) . At least 80% of the excess protoporphyrin has erythroid origin in human EPP (Bloomer et al., 1991) . Earlier studies have suggested that the liver might contribute significantly in some individuals (Lamon et al., 1980) , but the evidence is not very strong.
Liver transplantation has been performed in many EPP patients with endstage liver disease. Photosensitivity, although absent in some patients initially (Mion et al., 1992; Leone et al., 2000) , remains after transplantation (McGuire et al., 2005) . Recurrent graft disease occurred in 75% of patients after 7 years in the American cohort of 20 cases (McGuire et al., 2005) .
Gene therapy on hematopoietic cells cured photosensitivity in mice (Pawliuk et al., 1999; Fontanellas et al., 2001 ), but has not been attempted in man. The high frequency of graft disease recurrence after liver transplantation also argues against the feasibility of liverdirected gene therapy to prevent or cure significant liver disease in human EPP.
In our previously reported case (Wahlin et al., 2007) , HSCT as monotherapy cured all phenotypic signs of EPP. Liver biochemistry and porphyrin biochemistry in blood, urine, and feces have remained normal for more than 3 years that have now passed since HSCT. The FECH genotype is normal in peripheral blood cells, but the dermal genotype remains the same as before HSCT (Figure 1) . The patient has taken several trips to Mediterranean beach resorts, spending long days in the sun without experiencing any photosensitivity.
The understanding of the partially unresolved questions regarding the relative importance of erythroid, hepatic, and dermal FECH activity in human EPP has grown. It confirms what we thought we knew before the studies on mice were published. Although the experience may still be limited, these findings strengthen the concept of the bone marrow as the main source of protoporphyrin excess in human EPP. There is no clear evidence that the hepatocyte FECH deficiency is clinically relevant by itself, that dermal FECH deficiency is sufficient to cause photosensitivity, or that normalized FECH activity would cure photosensitivity in human EPP. The EPP mice models thus differ significantly from human EPP.
Effective treatments to prevent and treat cutaneous photosensitivity need to be devised. HSCT is the only curative option in human EPP, but is presently an option only for patients with protoporphyric liver disease (Wahlin and Harper, 2009). The mechanisms and determinants of liver injury caused by protoporphyrin remain elusive, but need to be delineated if patients suitable for curative HSCT are to be identified early, before the liver fails. 
